Dario Trapani and Maria Alice Borinelli-Franzoi explain a need of the oncology/cancer research community that led to the ESMO Precision Medicine Working Group driven project on developing a classification to categorise biomarkers to inform risk-guided intensity modulation of cancer treatments. They describe a methodology applied, how this will help shape better patient information, and explain prospect/utility of this new classification. Recommendations are published in the Annals of Oncology.
Original article: https://www.annalsofoncology.org/article/S0923-7534(22)00669-X/fulltext
Produced by the European Society for Medical Oncology